From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
BCL6-IN-6 is a potent inhibitor of transcriptional repressor B-cell lymphoma 6(BCL6).BCL6-IN-6 significantly blocks the interaction of BCL6 with its corepressors and reactivates BCL6 target genes in a dose-dependent manner. BCL6-IN-6 has the potential for the research of diffuse large B-cell lymphoma (DLBCL) .
TP-021 (BCL6-IN-8c) is a potent and orally active B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor with an IC50 of 0.10 µM in cell-free enzyme-linked immunosorbent assay .
BCL6 PROTAC 1 is a selective B-cell lymphoma 6(BCL6)PROTAC. BCL6 PROTAC 1 inhibits BCL6 cell reporter with an IC50 value of 8.8 µM. BCL6 PROTAC 1 significantly degrades BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6 PROTAC 1 can be used in tumor related research .
BCL6 Human Pre-designed siRNA Set A contains three designed siRNAs for BCL6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
BCL6-IN-9 (compound 1) is a potent B-cell lymphoma 6 protein (BCL6) inhibitor, with an IC50 of 3.9 nM. BCL6-IN-9 can be used for the research of cancer .
BCL6B Human Pre-designed siRNA Set A contains three designed siRNAs for BCL6B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SMRT peptide is one of the co-repressors of BCL6 BTB domain interaction. SMRT peptide binds to the BTB domain of BCL6 and enhances the transcriptional repression function of BCL6. SMRT peptide can be used to study protein-protein interactions .
BCOR(498-514), biotinylated is the minimal BCL6 binding domain with an KD value of 1.32 µM. BCOR(498-514), biotinylated blocks BCL6-mediated transcriptional repression and kills lymphoma cells .
WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .
F1324 acetate is a potent, high affinity peptidic inhibitor of B cell lymphoma 6(BCL6), with an IC50 of 1 nM. F1324 acetate exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .
F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6(BCL6) with an IC50 of 1 nM. F1324 exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .
F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6(BCL6), with an IC50 of 1 nM. F1324 TFA exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .
BCL6-IN-10 (Compound WK499) is a BCL6 inhibitor. BCL6-IN-10 interrupts the binding of BCL6 to SMRT protein. BCL6-IN-10 induces cell apoptosis, cell cycle arrest and DNA damage. BCL6-IN-10 inhibits AML cell proliferation (IC50s: 0.91, 1.63, 1.026, 7.42, 0.87, 0.85μM for OCl-AML3, THP1, MOLM13, HL60, KG1, NB4 cell respectively) .
BI-3802 is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity .
BI-3812 is a highly efficient BCL6 inhibitor that is capable of suppressing the BTB domain of BCL6, with an IC50 value of ≤ 3 nM, exhibiting antitumor activity .
CCT373566 is a potent and orally active degrader of transcriptional repressor BCL6, with an IC50 of 2.2 nM. CCT373566 shows strong antiproliferative efficacy in vitro and reduction in tumor growth in vivo .
CDK-TCIP1 is a bivalent molecule linking CDK9 inhibitor SNS-032 (HY-10008) to BCL6 ligand BI3812 (HY-111381). CDK-TCIP1 potently and specifically kills BCL6-overexpressing cells with EC50 of 7.7 nM for SUDHL5 cells .
CCT374705 is an orally active BCL6 inhibitor with potent antiproliferative effects in vitro. CCT374705 effectively inhibits tumor growth in a lymphoma xenograft mouse model .
CCT369260 (compound 1) is an orally avtive B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity. CCT369260 (compound 1) exhibits an IC50 of 520 nM .
TMX-2164 is a potent, irreversible B-cell lymphoma 6(BCL6) inhibitor with an IC50 value of 152 nM. TMX-2164 displays sustained target engagement and antiproliferative activity in cells .
ARV-393 is an orally active PROTAC that utilizes the ubiquitin-proteasome system to target the degradation of BCL6. ARV-393 consists of ligand conjugates targeting BCL6 and the E3 ligase cereblon, respectively. ARV-393 has DC50 and GI50 values of <1 nM in multiple cell lines of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ARV-393 also demonstrated considerable tumor suppressor activity in tumor xenograft models. ARV-393 is being studied to inhibit non-Hodgkin lymphoma.
TL4-12 is a selective MAP4K2/GCK inhibitor, dose-dependently downregulates IKZF1 and BCL-6 and leads to MM cell proliferation inhibition (IC50=37 nM) accompanied by induction of apoptosis. TL4-12 can be used to overcome immunomodulatory agent resistance in multiple myeloma (MM) .
DK-TCIP2, linking inhibitor of CDK9 SNS-032 (HY-10008) with ligands of BCL6 BI-3812 (HY-111381), is a anticancer agent. DK-TCIP2 shows anticancer activity in vivo and in vitro and can be used for study of lymphoma cancer .
JWZ-7-7-Neg1 is a transcriptional chemical inducers of proximity (TCIP) with negative chemical control. JWZ-7-7-Neg1 reduces the ability to bind to BRD4 or BCL6, so it has less cytotoxicity to DLBCL cells, in compared with JWZ-7-7 .
DZ-837 (compound 3d) is a PROTAC targeting BCL6 with a DC50 of approximately 600 nM. DZ-837 can induce cell cycle arrest and exert synergistic anticancer effects with Ibrutinib (HY-10997). DZ-837 is composed of PROTAC target protein ligand BCL6 ligand-2 (HY-161990) (red part), E3 ubiquitin ligase ligand Thalidomide-4-OH (HY-103596) (blue part), and PROTAC Linker (HY-W245803) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is 2-(2,6-Dioxopiperidin-3-yl)-4-((2-(2-hydroxyethoxy)ethyl)amino)isoindoline-1,3-dione (HY-W924949) [1] .
YCH2823 is an inhibitor of USP7 (IC50 = 49.6 nM; Kd = 0.117 μM). YCH2823 shows significant efficacy in inhibiting TP53 wild-type and mutant tumors, with approximately 5-fold higher potency than FT671. YCH2823 induce apoptosis. YCH2823 synergistic effects with mTOR inhibitors .
Transcription is the essential first step in the conversion of the genetic information in the DNA into protein and the major point at which gene expression is controlled. Transcription of protein-coding genes is accomplished by the multi-subunit enzyme RNA polymerase II and an ensemble of ancillary proteins, called transcription factors (TFs). Transcription factors play an important role in the long-term regulation of cell growth, differentiation and responses to environmental cues. Deregulated transcription factors contribute to the pathogenesis of a plethora of human diseases, ranging from diabetes, inflammatory disorders and cardiovascular disease to many cancers, and thus these proteins hold great therapeutic potential.
MCE offers a unique collection of 1,389 compounds with validated transcription factor targets modulating properties. MCE transcription factor-targeted compound library is an effective tool for researching transcription factors as drug targets as well as modulation of TFs for different therapeutic applications.
SMRT peptide is one of the co-repressors of BCL6 BTB domain interaction. SMRT peptide binds to the BTB domain of BCL6 and enhances the transcriptional repression function of BCL6. SMRT peptide can be used to study protein-protein interactions .
BCOR(498-514), biotinylated is the minimal BCL6 binding domain with an KD value of 1.32 µM. BCOR(498-514), biotinylated blocks BCL6-mediated transcriptional repression and kills lymphoma cells .
F1324 acetate is a potent, high affinity peptidic inhibitor of B cell lymphoma 6(BCL6), with an IC50 of 1 nM. F1324 acetate exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .
F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6(BCL6) with an IC50 of 1 nM. F1324 exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .
F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6(BCL6), with an IC50 of 1 nM. F1324 TFA exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .
BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human (GST) is the recombinant human-derived BCL6 protein, expressed by E. coli , with N-GST labeled tag. The total length of BCL6 Protein, Human (GST) is 706 a.a., with molecular weight of ~105.5 kDa.
BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human is the recombinant human-derived BCL6 protein, expressed by E. coli , with tag free. The total length of BCL6 Protein, Human is 706 a.a., with molecular weight of 79.0 kDa.
BCORL1 Protein, Human (His, Strep) is the recombinant human-derived BCORL1, expressed by E. coli , with Strep, His labeled tag. The total length of BCORL1 Protein, Human (His, Strep) is 118 a.a.,
BCL6; BCL5; LAZ3; ZBTB27; ZNF51; B-cell lymphoma 6 protein; BCL-6; B-cell lymphoma 5 protein; BCL-5; Protein LAZ-3; Zinc finger and BTB domain-containing protein 27; Zinc finger protein 51
IHC-P
Human
Bcl6 Antibody (YA1281) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1281), targeting Bcl6. Bcl6 Antibody (YA1281) can be used for IHC-P experiment in human background.
BCL6 Human Pre-designed siRNA Set A contains three designed siRNAs for BCL6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
BCL6B Human Pre-designed siRNA Set A contains three designed siRNAs for BCL6B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
